Mary Wilson
Well-known member
Pharma giant expects to ship half the doses it had originally planned after finding raw materials in early production didn’t meet its standards
By Costas Paris
Updated Dec. 3, 2020 6:58 pm ET
When Pfizer Inc. said last month it expects to ship half the Covid-19 vaccines it had originally planned for this year, the decision highlighted the challenges drug makers face in rapidly building supply chains to meet the high demand.
“Scaling up the raw material supply chain took longer than expected,” a company spokeswoman said. “And it’s important to highlight that the outcome of the clinical trial was somewhat later than the initial projection.”
https://www.wsj.com/articles/pfizer...s-11607027787?reflink=desktopwebshare_twitter
By Costas Paris
Updated Dec. 3, 2020 6:58 pm ET
When Pfizer Inc. said last month it expects to ship half the Covid-19 vaccines it had originally planned for this year, the decision highlighted the challenges drug makers face in rapidly building supply chains to meet the high demand.
“Scaling up the raw material supply chain took longer than expected,” a company spokeswoman said. “And it’s important to highlight that the outcome of the clinical trial was somewhat later than the initial projection.”
https://www.wsj.com/articles/pfizer...s-11607027787?reflink=desktopwebshare_twitter